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Abstract We conducted four rounds of cognitive testing
of self-report items that included 66 sociodemographically
diverse participants, then field tested the three best items
from the cognitive testing in a clinic waiting room
(N = 351) and in an online social networking site for men
who have sex with men (N = 6,485). As part of the online
survey we conducted a randomized assessment of two
versions of the adherence questionnaire—one which asked
about adherence to a specific antiretroviral medication, and
a second which asked about adherence to their ‘‘HIV
medicines’’ as a group. Participants were better able to
respond using adjectival and adverbial scales than visual
analogue or percent items. The internal consistency reli-
ability of the three item adherence scale was 0.89. Mean
scores for the two different versions of the online survey
were similar (91.0 vs. 90.2, p \ 0.05), suggesting that it is
not necessary, in general, to ask about individual
medications in an antiretroviral therapy regimen when
attempting to describe overall adherence.
Keywords HIV  Medication adherence 
Self-report  Questionnaires  Survey methodology
Introduction
While a wide variety of self-report measures have been
developed to assess adherence with HIV ART, few of the
questionnaire items that make up these measures have been
subjected to rigorous cognitive testing to ensure that the
items are consistently understood by respondents. Accurate
self-reports of medication could be useful in routine clin-
ical care because research has consistently shown that
physicians’ assessment of their patients’ adherence with
ART is inaccurate [1–4]. They could also be useful for
research when more objective measures such as MEMS
caps [5] or unannounced pill counts [6, 7] are impractical
or too costly [8, 9].
A number of self-report measures of medication adherence
have been developed for chronic medical conditions such as
hypertension and diabetes (e.g., Morisky), with different
levels of validity testing [10–13]. For HIV, a wider variety of
instruments have been developed and used [14].The validity
of these instruments has been assessed, in general, by
examining their relationship to laboratory outcomes, most
commonly viral loads. Correlations with viral loads are con-
sistently in the 0.3–0.4 range [14, 15], and sometimes a little
better. Previous work by our group showed that a rating item
performed better than either a frequency item or a percent
item using electronic drug monitoring (MEMS) as a gold
standard [16]. Subsequent work by others has confirmed this
finding [17, 18]. However, little is known about why certain
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items appear to perform better than others [15], or whether
further improvements can be made.
Another important issue for survey designers is whether
it is necessary to ask about each of the individual medi-
cations that make up an antiretroviral therapy regimen, or
whether one can ask about the regimen in the aggregate.
Relatively few papers have attempted to assess differential
adherence [19–23]. While some of these studies suggest
that it is not necessary to measure individual medications
[19, 20, 23], these were relatively small, single site studies,
and other studies suggest that differential adherence may
be consequential [21, 22]. Thus it remains unclear whether
the extra effort needed to measure adherence with each
component of a regimen, which in the case of a three-drug
regimen triples the respondent burden, is worthwhile.
To better understand why some items perform better than
others, and to try to optimize the quality and performance of
such measures, we conducted an extensive, iterative series of
in-depth cognitive interviews with a socioeconomically and
demographically diverse group of patients with HIV in
Massachusetts and Rhode Island to find out how they
understood the survey items. We then conducted pilot tests of
the best items in over 350 patients who completed a pencil-
and-paper version of the survey, and over 6,400 patients who
completed an online version of the survey. The online version
included a randomized test of whether responses differed if
respondents focused on an individual medication or the
antiretroviral regimen as a whole. We had three specific study
questions: (1) Which item stems were most consistently
understood by respondents and which response tasks could
respondents use best to provide answers? (2) Can patients
respond accurately to questions about their whole ART reg-
imen or is it necessary to ask questions about individual pills
in the regimen? (3) What are the psychometric characteristics




Cognitive interviews allow researchers to: learn about
respondents’ comprehension of candidate survey items;
identify any unclear concepts, questions, or terms; and
evaluate whether or not the answer provided accurately
reflects what respondents have to report.
Participants
Subjects for the cognitive testing were recruited from the
HIV clinics at two urban Academic Medical Centers in MA
and RI. Eligible patients where those who were taking
antiretroviral therapy, taking at least one other daily med-
ication for a chronic condition, spoke English, and had at
least one detectable HIV plasma viral load in the last two
recorded tests. The criterion of taking at least one other
daily medication for a chronic condition was so we could
determine whether these items worked equally well for
ART and medications for other conditions. Potential sub-
jects were identified by signs in the exam rooms (self-
referral), recommendations from treating physicians, and
medical record reviews. They were paid $80 dollars for up
to 2 h of their time. A total of 270 patients were screened,
81 proved to be eligible, and 66 completed an interview. Of
the 15 who did not complete an interview, five did not
show up for their appointments, two cancelled their
appointments before the scheduled time, one decided not to
participate after arriving for the appointment but before
consenting, and seven did not return calls to schedule an
interview. There were no significant differences (p \ 0.05)
between participants and non-participants in age and gen-
der (the only available variables).
Questionnaires and Interview Process
Strategy Our goals were to identify items and response
categories that were relatively simple, and consistently
understood by respondents from different socioeconomic
backgrounds. Concepts we explored included being adher-
ent for a specific period versus generally adherent; the kinds
of specific tasks that respondents could understand and
recall (taking, missing, ability to take, etc.); adherence
(execution or implementation of a regimen) versus persis-
tence (stopping altogether); comprehension of different
response tasks (yes/no, visual analogue scales, numbers/
percents vs. adjectives/adverbs) and the problems or biases
that existed with each; and whether responses would be
clinical meaningful or interpretable. In addition, although it
is difficult, we tried to minimize phrasing the might increase
social desirability pressures to overreport adherence such as
‘‘missing doses’’. Finally, we also wanted to design an
instrument that was simple enough to be self-administered.
Item selection The questionnaire design process began by
collecting as many instruments and items as we could that
had attempted to measure self-reported medication adher-
ence. We first conducted a literature review using combina-
tions of the following search terms: HIV, highly active
antiretroviral therapy, medication adherence, self-report,
questionnaires, survey methodology. In addition we
reviewed references of review articles and directly contacted
a number of investigators. There were dozens of such ques-
tions that varied in their reference period, how they were
worded, what respondents were supposed to report about, and
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the response tasks respondents were supposed to use to
provide answers (a detailed list of the items we considered is
available from the first author upon request). We focused our
initial attention on the question wording and response tasks
that seemed to be used most often and had the strongest face
validity.
Cognitive testing protocol We conducted four rounds of
cognitive testing. In the first three rounds first asked the
respondents to list the medicines they were taking. The
instruments asked one series of questions about an HIV
medication and another series about a medication they
were to take daily for another chronic condition. This
approach gave us an opportunity to use the cognitive
interview to insure that the items worked similarly for other
(non-antiretroviral) medications. The initial instrument we
created asked various types of questions for 1 week and
1 month reference periods and included questions with
several different response tasks. The instrument for the
second round included some new concepts that had not
been included in the first round. We also began to test
slightly reworded questions that had been changed to
address issues identified in the first round. The third round
of questions consisted of what we considered to be the
strongest candidates for a final instrument. A final fourth
round, shorter than the previous instruments, consisted of a
short list of questions that we believed would constitute our
final instrument. The specific items tested in each of these
rounds are available from the corresponding author upon
request.
The cognitive interview consisted of two parts. First,
respondents completed all of the questions in a self-
administered paper form. The interviewer then went back
over the questions, one by one and talked to the respondent
about their responses. Interviewers used a semi-structured
protocol that included a set of probes for each question that
was designed to help understand how respondents under-
stood questions and went about answering them. Before
completing the discussion of each question, interviewers
were instructed to use additional probes as needed to col-
lect information about each of the four elements of ques-
tion answering identified by Tourangeau: comprehension,
retrieval, transformation, and providing an answer [24, 25].
Interviews were audio-taped, with respondent permission.
Interviewers then could use the tape recording to help write
up their observations about question issues after each
interview had been completed. Interviewers were debriefed
by investigators at the UMASS Center for Survey
Research, and changes to the instrument were made based
on the cognitive testing results.
Analyses The results from the cognitive testing were used
in two ways to evaluate the questions. First, interviewers
reported on their experiences with each of the four ele-
ments of the questions answering process (comprehension,
retrieval, transformation and answering) plus the use of the
reference period for each question. Second, since a number
of questions were asked that essentially addressed how well
medications were taken, we looked at the consistency of
answers across questions. One specific approach that we
relied on most looked at the number of days in the past
month respondents said they had missed taking any med-
ications. Answers to other questions were tabulated by
whether the respondent reported missing no medications or
reported missing at least one. The more answers to other
questions seemed inconsistent with the number of missed
medications reported, the more concern there was about the
reliability of those answers. After four rounds of testing,
three items clearly emerged as the best items, and those
were rotated forward into pilot testing.
Field Testing
Participants
The three items that emerged from the cognitive testing
were then pilot tested in two settings. A pencil and paper
version of the survey was conducted in the same two
clinics where the cognitive testing was done. Patients were
invited to participate, given the short (two sides of a page)
survey, and told where they could anonymously return it by
depositing it in a locked box. All patients who had not
participated in the cognitive testing and were using HIV
antiretroviral medications were eligible.
Cross-sectional, national, internet-based surveys were
administered to U.S. based members of one of the most
popular American social networking site for gay and
bisexual men and other men who have sex with men
(MSM), administered by the OLB Research Institute at
Online Buddies, Inc.
Questionnaires
The pencil-and-paper version of the questionnaire included
an item asking how many different HIV medicines the
subject takes, the three adherence questions, and items
about how long ago the patient first started taking antiret-
rovirals, gender, age, education, ethnicity, and race. For
each of the three items asking about antiretroviral medi-
cation adherence, this pencil-and-paper version of the
questionnaire used the phrase their ‘‘HIV medicines’’
which we had determined in the cognitive testing was
consistently understood as referring to HIV antiretroviral
medications.
The web version of the survey was randomized into two
versions which allowed us to test whether patients
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responded differently when asked about ‘‘your HIV med-
ications’’ as a group compared with asking about individual
HIV medications one at a time. Half of the patients who
took the web version were shown a color chart of all HIV
antiretroviral agents currently on the market in pill form,
and then presented with an alphabetical list of all of the
medications. These patients were then asked: ‘‘FROM
THIS LIST, CHOOSE ONE OF THE HIV MEDICINES
THAT YOU ARE TAKING.’’ A picture of the selected
medication was shown for confirmation. The name of that
medication was included in all subsequent items. For
example, if a patient chose Atripla as their medication, an
item on the survey would appear as follows: ‘‘Now think
about the last 30 days. How would you rate how well you
did taking your Atripla?’’ The other half of the respondents
received a survey which asked about ‘‘your HIV medi-
cines’’ as a group, in the same way the items appeared on
the pencil and paper survey.
Analyses
We calculated descriptive statistics for the pencil and paper
and both arms of the web survey. Item responses for the
three adherence items were linearly transformed to a 0–100
scale [26, 27]. A summary of the individual adherence
items was calculated as the mean of the three individual
items. We assessed the internal reliability consistency of
the resulting scale using Cronbach’s alpha. Differences
between the two arms of the web survey and between the
web survey in the pencil and paper survey were assessed by
Chi square tests for dichotomous and categorical variables,




Sixty-six individuals participated in the four rounds of
cognitive testing. Of the 66, 70 % were male, median age
was 51 years, 71 % had education of high school or less,
59 % were non-white, and 5 % were Hispanic.
Lessons Learned
The following are some of the key findings from the cog-
nitive interviews (Table 1). Most subjects were unable to
construct a medication list from memory. Pills versus non-
pill medications (e.g., inhalers) also caused confusion, and
some participants did not know how to report on pills taken
‘‘as needed.’’
One focus of testing was to learn about what the best
‘‘reference period’’ was and how to describe that reference
period. There proved to be no consistent understanding of
‘‘the last week’’ or ‘‘the last month.’’ The phrase ‘‘the last
week’’ was interpreted variably as the last 7 days, the pre-
vious Monday to Sunday interval, and the previous Sunday
to Saturday interval. The same was true for ‘‘the last month.’’
Subjects had a much more consistent understanding of time
periods when expressed as number of days, such as ‘‘the last
7 days’’ or ‘‘the last 30 days.’’ Despite this general under-
standing, overall, subjects’ attention to the reference period
was poor. They tended to answer generally about the time
period rather than focus on the exact time period. Also, as
one would expect, ability to retrieve details was worse for
30 days than for 7 days. However, respondents found it
difficult to recall precisely for either reference period.
We tested a series of questions that asked about taking
medicine ‘‘exactly as the doctor prescribed.’’ Subjects
found this difficult for several different reasons. One
problem is that it is not always a physician that does the
prescribing. Another problem was that doctors differ in the
extent to which they describe how medicines should be
taken, with some giving little instruction, and others giving
more. However, even if a physician did provide instruc-
tions, patients often could not remember the details of the
instructions. We tested several variations to solve this
problem, and patients most consistently understood the




Time frame No consistent understanding of ‘‘the last
week’’ or ‘‘the last month’’; better the
last 7 or 30 days
Attention to reference
period
Attention to the reference period was poor


















Words vs. numbers Subjects level of recall is more
appropriate to verbal than numerical
answers and subjects more comfortable
with adjectives and adverbs than
numbers as way of providing answers
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questions that used the phrase ‘‘the way you are supposed
to take’’ your medicine.
We found that subjects usually had a consistent under-
standing of the concept of a ‘‘dose.’’ However, there was
inconsistent application of this concept when answering the
actual survey questions, particularly in cases where there
was twice a day dosing.
With regard to response options, both visual analogue
scales and asking about percents worked relatively poorly.
Most people have to do some math to respond to these
questions, and they often make errors when they do.
Moreover, there are some subjects who made a guess or an
estimate without doing any math. In general, we found that
participants were not consistently able to understand and
apply fractions or percentages.
A scale that ranged from ‘‘very poor’’ to ‘‘perfect’’ did not
work well. Some subjects answered by saying that ‘‘no one is
perfect.’’ Many refused to endorse ‘‘perfect’’ even when their
adherence was 100 % on other scales. There was also con-
fusion about a scale we tested that asked ‘‘Overall, how do
you feel about the way you took [medication name] in the last
7 days?’’ Response options ranged from delighted to terrible.
This caused confusion between how they felt physically and
how they took their medications. Also, ‘‘delighted’’ was not a
term that many associated with medication taking.
In general, subjects were more comfortable and confident
using adjectives and adverbs as response options than they
were with quantitative assessments. One partial reason is that,
as we noted above, detailed recall was far from perfect. The
level of detail respondents could recall was more appropriate
for verbal than quantitative answers. For those with less than
perfect adherence, as previously noted, subjects tended to
estimate rather than count or enumerate, and words seem to
map onto this cognitive estimation process more accurately
and more comfortably for most patients than numbers.
The three best performing items are shown in the
Appendix.
Pilot Testing of the Three Best Performing Items
Descriptive Characteristics
Not surprisingly the web-based and clinic-based samples
were different from each other (Table 2). The web-based
sample was more male (\99 vs. 75 %), less Hispanic (9 vs.
19 %), less African-American (5 vs. 25 %), and better
educated (88 % education beyond high school vs. 59 %).
Inquiring About Whole ART Regimen Versus Individual
Pills
Scores on each of the three items, and on the summary
three-item scale, were similar between the randomized
groups (Table 3). Regarding the randomized comparison,
the adherence scale score for the single item scale was
slightly higher than the adherence scale score for the item
that asked about the whole regimen (91.0 vs. 90.2,
p \ 0.05). Though it was statistically significant, given
the magnitude of this difference (0.8 points on a 100
scale), we did not consider this difference clinically
important. The difference between the whole regimen arm
of the web-based trial and the clinic sample was greater
(90.2 vs. 88.8), but because clinic patients were not
included in the randomization, direct comparisons are not
appropriate. Given the sociodemographic characteristics
of the clinic sample (more women, more persons of color,
lower educational levels) one might anticipate lower
adherence.
Item and Scale Distributions
Because the item and scale distributions were so similar,
we combined them for purposes of illustrating their dis-
tributions (Fig. 1). All were skewed upward. The medians
for the three items were all 100, and the median for the
Table 2 Participant characteristics






Age [mean years (SD)] 46.7 (10.0) 47.2 (10.0) 49.4 (9.7)
Gender (% male) 99.3 99.4 75.1
Hispanic (%) 9.5 8.9 19.0
Race (%)b
White 89.5 89.1 57.0
African American 4.7 5.1 25.1
Asian 1.2 1.2 1.7
Pacific Islander 0.4 0.3 0.3
Native American 1.8 1.6 4
Other 4.4 5.0 14.5
Education
8th grade or less 0.2 0.2 4.0






Some college or 2-year
degree
34.6 34.9 33.0




a Those who agreed to participate among N = 3724 (One med) and
N = 3768 (all meds)
b Sum of the percent is [100 because of multiple responses
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scale was 98.9 (data not shown). The percent scoring at the
ceiling for the ‘‘days not missed,’’ ‘‘how good a job’’, ‘‘how
often,’’ and summary items were 58, 60, 62, and 54 %
respectively. Those not scoring at the ceiling of the three-
item scale used the full range of the rest of the 0–100 scale.
Internal Consistency Reliability
The Cronbach’s alphas for the three-item scale (Table 3)
were quite high for all three samples (0.86–0.89).
Discussion
There were three main findings from these analyses. First,
the four rounds of cognitive testing allowed us to develop a
set of items that we believe can be consistently understood
by respondents from diverse sociodemographic and edu-
cational backgrounds. Second, the randomized experiment
showed convincingly that the adherence scores did not
differ between those asked about ‘‘all your HIV medica-
tions’’ and those who responded with a specific medication
in mind. Third, in pilot testing the internal consistency
reliability of three item scale was excellent.
We think results from cognitive interviewing can and
should be more explicitly presented as a way of docu-
menting the strengths and weaknesses of survey questions.
Because in this case so many of the commonly used
approaches to asking questions about medication taking
proved unworkable in our cognitive testing, we thought
that it would be useful to describe our findings—for
example, the inconsistency with which patients understood
concepts such as the ‘‘last week’’ or the ‘‘last month, the
ambiguity of the term ‘‘as prescribed,’’ the confusion that
visual analogue scales and percents created for many
respondents, and the fact that patients were generally more
comfortable using words than numbers in responses. While
we tested these issues in two HIV care settings, we suspect
that many of the findings would be generalizable to other
populations being asked similar questions.
In previous work that used electronic drug monitoring as
a reference we found that a rating scale performed better
than other response sets [16] in correlating with the
objective measure of adherence, and other investigators
using the same rating item have since reported similar
findings [17, 18]. We had previously speculated that the
cognitive process of coming up with an adjectival rating
appeared to correspond more closely to objective adher-
ence data because it mapped more closely onto the cog-
nitive process that patients used to form responses, which
we thought was probably more an estimation process than
an enumeration process. Our cognitive testing supports this
theory. Only about half of respondents could demonstrate
sufficient recall to describe details of their pill taking over a
30 days period. The majority were clearly estimating.
Interestingly, the rating item that we tested previously
[16] was worded as follows: ‘‘Thinking back over the last
month, on average how would you rate your ability to take
all your [HIV] medications as prescribed.’’ (response
options very poor to excellent) Even though the perfor-
mance of this item has been excellent, our cognitive testing
showed that respondents did not have a consistent under-
standing of either the ‘‘last month,’’ ‘‘rate your ability’’ or
‘‘as prescribed.’’ This led us to modify the question in ways
that led to the current version, ‘‘In the last 30 days, how
good a job did you do at taking your HIV medications in
the way you were supposed to.’’
There is a small literature that addresses the issue of
whether adherence differs in clinically important ways
among the individual medications that make up HIV anti-
retroviral regimens. Wilson et al. [19] using self-report
measures from multiple individual antiretrovirals, con-
cluded that patients tended to take (or not take) the indi-
vidual antiretrovirals in their regimen as a group rather than
taking some but not others at a given dosing time. McNabb
et al. [20] used electronic drug monitoring pill caps (Aprex)
and found very little differential adherence for different
medications scheduled to be taken at the same time. Des-
champs et al. [23] found little differential adherence using a
self-report measure. Gardner et al. used pharmacy refill data
and found that 15 % of patients in an unselected clinical
population had ‘‘selective adherence,’’ defined as C5 %
difference between two drugs in a regimen over an obser-
vation period of at least 60 days [21]. In a subsequent paper
from a randomized trial Gardner et al. used self-report to
assess differential adherence. Adherence was assessed sep-
arately for each component of the regimen, and patients
Table 3 Descriptive data on adherence items (0–100 scale, see
Appendix for exact wording)








95.8 (11.4) 95.1 (12.9)* 94.7
(14.1)
How good a job did
you do…
87.8 (19.8) 86.8 (20.9) 84.2
(21.7)*
How often did you
take…
89.7 (17.3) 88.8 (18.1)* 88.0
(19.9)
Mean of the three
item scales
91.0 (14.6) 90.2 (15.8)* 88.8
(17.1)*
Cronbach’s alpha 0.86 0.89** 0.89*
Using One med as a reference, scales were compared by t test (Non
parametric tests’ results were the same) and Cronbach’s alpha were
compared by Fisher’s z-transformation
* p value \0.05, ** p value \0.01
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were classified as having differential adherence if the
assessments disagreed. In the 60 month trial with assess-
ments every 4 months, 29 % reported differential adherence
at least once, and 10 % reported it more than once [22].
While differential adherence clearly exists, and is
probably clinical consequential [22], this research addres-
ses a practical measurement question, not a clinical ques-
tion. We tested the hypothesis that we would get
quantitatively different results if we asked about patients’
global adherence with their HIV medications than if we
asked them to respond with reference to a single, individual
medication. In a web-based trial that had over 3,000
responses in each arm, the difference in the three-item
scale was 0.8 points on a 100 scale (91.0 vs. 90.2). While
this was significant at the level of p \ 0.05, we do not think
that this difference is clinically important.
We think the results of this web-based trial are useful
because being able to ask respondents to report about their
antiretroviral regimen overall is far simpler, and far less
burdensome, than identifying individual medications and
then asking questions about each one of them. The very small
difference that we observed between arms was in the expected
direction. Because we know that there is some differential
adherence, we hypothesized that asking about non-adherence
with three medications would be more sensitive than asking
about non-adherence with a single medication. In short, we
believe the data we present here supports the assertion that for
most clinical and research applications it is reasonable to use
these self-report items with reference to patients’ entire
antiretroviral regimen. That said, for investigators interested
specifically in differential adherence, these three items can be
repeated for each of the pills in a regimen.
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0 10 20 30 40 50 60 70 80 90 100
In the last 30 days, on how many days did you miss at 
least one dose of any of your HIV medicines (figure 
shows 30 minus the response, or days not missed ?)
In the last 30 days, how good a job did you do at 
taking your HIV medicines in the way you were 
supposed to?
Distribution of 3 item scale scores (0-100)*In the last 30 days, how often did you take your HIV medicines in the way you were supposed to? 
* Those at “100” include values 96-100 
Fig. 1 Distributions of the three items and the summary scale
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One of the primary challenges to measuring any socially
desirable behavior by self-report is avoiding ceiling effects.
That is, to the extent possible, one would like to avoid the
problem of respondents over-reporting their adherence in
such a way that all or most score at the top of the scale.
This type of measurement error results in a measure with
little useful variation to explore analytically. Of course, if
the surveyed respondents were in fact highly adherent, then
ceiling effects would be a function of the true underlying
behavior rather than a type of measurement error. In this
study, because we have no objective adherence measure
with which to compare our adherence measures, we cannot
identify the portion of our measurement that is error, and
we cannot directly compare our findings with other studies
that use related items in different populations [16–18].
However, in very recent reports, full or excellent adherence
with current antiretroviral regimens has been reported in
many settings to be quite high [28, 29].
This study has several limitations. First, it was not pos-
sible to do cognitive testing of all of the different items and
response scales that have been used for self-report of med-
ication adherence. We used judgment to select which items
to test, and it is possible that other items or approaches would
also have fared well in cognitive tests. Second, although we
purposefully conducted our cognitive testing in a socio-
demograpically diverse sample of persons with HIV, it is
possible that testing in other populations would yield dif-
ferent results. Third, our web-based sample was largely well
educated, gay, white men, and it is possible that the findings
from the randomized experiment we conducted would have
been different in a different population. Arguing against this
is the fact that the distributional and psychometric charac-
teristics from the clinic-based sample were strikingly similar
to the web-based sample despite very different sample
characteristics. Fourth, we cannot assess whether partici-
pants in the web-based survey did so fraudulently, as some
have described [30]. Fifth, while we have presented findings
from cognitive and psychometric testing, until we complete
testing currently underway that includes an objective
adherence measure as a comparator, we cannot make any
statements about the validity of items or the scale. Finally,
the use of these items in non-English speaking settings will
require both careful translation and back translation [31, 32]
and additional cognitive testing.
In conclusion, through detailed cognitive testing we
have developed a new, short set of medication adherence
self-report items. Next, in a large field test, we found that
asking patients to report on adherence with their whole
antiretroviral regimen produced similar results to asking
them about individual medications. The three items and the
resulting adherence scale had good distributional charac-
teristics and an excellent Cronbach’s alpha. Both the les-
sons from our cognitive testing and the resulting items
should be applicable to self-report of other medications
used chronically for other conditions. Formal validity
testing is underway, and rigorous testing of these items in a
variety of other settings is encouraged.
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